These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 24410307)

  • 41. Efficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and children.
    Silverstein BE; Allaire C; Bateman KM; Gearinger LS; Morris TW; Comstock TL
    Clin Ther; 2011 Jan; 33(1):13-26. PubMed ID: 21397770
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics.
    Mather R; Karenchak LM; Romanowski EG; Kowalski RP
    Am J Ophthalmol; 2002 Apr; 133(4):463-6. PubMed ID: 11931779
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The in vivo rat skin photomicronucleus assay: phototoxicity and photogenotoxicity evaluation of six fluoroquinolones.
    Reus AA; Usta M; Kenny JD; Clements PJ; Pruimboom-Brees I; Aylott M; Lynch AM; Krul CA
    Mutagenesis; 2012 Nov; 27(6):721-9. PubMed ID: 22935223
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety of fluoroquinolones.
    Barberán J; de la Cuerda A; Tejeda González MI; López Aparicio A; Monfort Vinuesa C; Ramos Sánchez A; Barberán LC
    Rev Esp Quimioter; 2024 Apr; 37(2):127-133. PubMed ID: 38140798
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Fluoroquinolone-related neuropsychiatric and mitochondrial toxicity: a collaborative investigation by scientists and members of a social network.
    Kaur K; Fayad R; Saxena A; Frizzell N; Chanda A; Das S; Chatterjee S; Hegde S; Baliga MS; Ponemone V; Rorro M; Greene J; Elraheb Y; Redd AJ; Bian J; Restaino J; Norris LB; Qureshi ZP; Love BL; Brookstaver B; Georgantopoulos P; Sartor O; Raisch DW; Rao G; Lu K; Ray P; Hrusheshky W; Schulz R; Ablin R; Noxon V; Bennett CL;
    J Community Support Oncol; 2016 Feb; 14(2):54-65. PubMed ID: 26955658
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Association between recent use of fluoroquinolones and rhegmatogenous retinal detachment: a population-based cohort study.
    Kuo SC; Chen YT; Lee YT; Fan NW; Chen SJ; Li SY; Liu CJ; Chen TL; Chen TJ; Fung CP
    Clin Infect Dis; 2014 Jan; 58(2):197-203. PubMed ID: 24170197
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Biological and chemical changes in fluoroquinolone-associated tendinopathies: a systematic review.
    Bisaccia DR; Aicale R; Tarantino D; Peretti GM; Maffulli N
    Br Med Bull; 2019 Jun; 130(1):39-49. PubMed ID: 30811525
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Fuzzy Comprehensive Evaluation Assistant 3D-QSAR of Environmentally Friendly FQs to Reduce ADRs.
    Ren Z; Wang Y; Xu H; Li Y; Han S
    Int J Environ Res Public Health; 2019 Aug; 16(17):. PubMed ID: 31470687
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Adverse effects and interactions of fluoroquinolones].
    Sepcić K; Perković O; Turel I; Sepcić J
    Lijec Vjesn; 2009; 131(3-4):74-80. PubMed ID: 19514253
    [TBL] [Abstract][Full Text] [Related]  

  • 50. What Is Old Is New Again: Delafloxacin, a Modern Fluoroquinolone.
    Cho JC; Crotty MP; White BP; Worley MV
    Pharmacotherapy; 2018 Jan; 38(1):108-121. PubMed ID: 29059465
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Reliability of phototoxic tests of fluoroquinolones in vitro.
    Zhang T; Li JL; Ma XC; Xin J; Tu ZH
    Acta Pharmacol Sin; 2003 May; 24(5):453-9. PubMed ID: 12740182
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Latest industry information on the safety profile of levofloxacin in Japan.
    Yagawa K
    Chemotherapy; 2001; 47 Suppl 3():38-43; discussion 44-8. PubMed ID: 11549788
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fluoroquinolone toxicities. An update.
    Lietman PS
    Drugs; 1995; 49 Suppl 2():159-63. PubMed ID: 8549287
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A critical review of the fluoroquinolones: focus on respiratory infections.
    Zhanel GG; Ennis K; Vercaigne L; Walkty A; Gin AS; Embil J; Smith H; Hoban DJ
    Drugs; 2002; 62(1):13-59. PubMed ID: 11790155
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Detection of fluoroquinolone-induced tendon disorders using a hospital database in Japan.
    Hori K; Yamakawa K; Yoshida N; Ohnishi K; Kawakami J
    Pharmacoepidemiol Drug Saf; 2012 Aug; 21(8):886-9. PubMed ID: 22532516
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adverse reactions of fluoroquinolones to central nervous system and rational drug use in nursing care.
    Haiping L; Ziqiang J; Qina Z; Yuhua D
    Pak J Pharm Sci; 2019 Jan; 32(1(Special)):427-432. PubMed ID: 30852480
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety and tolerability of intravenous-to-oral treatment and single-dose intravenous or oral prophylaxis with trovafloxacin.
    Williams DJ; Hopkins S
    Am J Surg; 1998 Dec; 176(6A Suppl):74S-79S. PubMed ID: 9935261
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Adverse drug reactions: implications for the development of fluoroquinolones.
    Ball P
    J Antimicrob Chemother; 2003 May; 51 Suppl 1():21-7. PubMed ID: 12702700
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Analyses of fluoroquinolones and Clostridium difficile-associated diarrhoea in tuberculosis patients.
    Chang KC; Leung CC; Yew WW; Lam FM; Ho PL; Chau CH; Cheng VC; Yuen KY
    Int J Tuberc Lung Dis; 2009 Mar; 13(3):341-6. PubMed ID: 19275794
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Fluoroquinolone safety in pediatric patients: a prospective, multicenter, comparative cohort study in France.
    Chalumeau M; Tonnelier S; D'Athis P; Tréluyer JM; Gendrel D; Bréart G; Pons G;
    Pediatrics; 2003 Jun; 111(6 Pt 1):e714-9. PubMed ID: 12777590
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.